# Petco Health & Wellness Company, Inc.: Form 10-Q for the period ended Nov 2, 2024

- Company: [Petco Health & Wellness Company, Inc.](/companies/woof.md) (CIK 1826470)
- Form: 10-Q
- Filed: 2024-12-06
- Accepted by EDGAR: Dec 6, 2024, 21:05 ET
- Period: 2024-11-02
- Accession: 0000950170-24-134077
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1826470/000095017024134077/woof-20241102.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1826470/000095017024134077/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-11-02.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-08-04 to 2024-11-02 | $1.51bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2024-02-04 to 2024-11-02 | $4.56bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-08-04 to 2024-11-02 | $935.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2024-02-04 to 2024-11-02 | $2.83bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2024-08-04 to 2024-11-02 | $575.8m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2024-02-04 to 2024-11-02 | $1.74bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2024-08-04 to 2024-11-02 | $571.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2024-02-04 to 2024-11-02 | $1.75bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-08-04 to 2024-11-02 | $4.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-02-04 to 2024-11-02 | −$10.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-08-04 to 2024-11-02 | −$857.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-02-04 to 2024-11-02 | −$10.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-08-04 to 2024-11-02 | −$16.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-02-04 to 2024-11-02 | −$88.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-08-04 to 2024-11-02 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-02-04 to 2024-11-02 | −$0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-08-04 to 2024-11-02 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-02-04 to 2024-11-02 | −$0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-08-04 to 2024-11-02 | 274,495,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-02-04 to 2024-11-02 | 272,446,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-02-04 to 2024-11-02 | $81.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-02-04 to 2024-11-02 | $91.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-11-02 | $116.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-11-02 | $931.8m | us-gaap:AssetsCurrent |
| Total assets | at 2024-11-02 | $5.21bn | us-gaap:Assets |
| Current liabilities | at 2024-11-02 | $1.11bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-11-02 | $4.09bn | us-gaap:Liabilities |
| Long-term debt | at 2024-11-02 | $1.58bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2024-11-02 | $1.12bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 36,573 characters.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the accompanying notes included elsewhere in this Quarterly Report on Form 10-Q (this “Form 10-Q”), as well as the corresponding Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended February 3, 2024 (the “2023 Form 10-K”). The discussion and analysis below contains certain forward-looking statements about our business and operations that are subject to the risks, uncertainties, and other factors referred to in Part II, Item 1A, “*Risk Factors”* of this Form 10-Q. These risks, uncertainties, and other factors could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements. The risks described in this Form 10-Q and in other documents we file from time to time with the U.S. Securities and Exchange Commission (the “SEC”), including the section entitled “Forward-Looking Statements” in this Form 10-Q, should be carefully reviewed. All amounts herein are unaudited.

### Overview

Petco Health and Wellness Company, Inc. (“Petco”, the “Company”, “we”, “our” and “us”) is a pet health and wellness company focused on improving the lives of pets, pet parents, and our own partners. Through our omnichannel ecosystem, we provide our customers with a comprehensive offering of products and services to fulfill their pets’ health and wellness needs through our more than 1,500 pet care centers in the U.S., Mexico, and Puerto Rico, including a network of in-store veterinary hospitals, our digital channel, and our flexible fulfillment options.

Our multicategory strategy integrates our digital assets with our nationwide physical footprint to meet the needs of pet parents who are looking for a single source for all their pets' needs. Our e-commerce site and mobile app serve as hubs for pet parents to manage their pets’ health, wellness, and merchandise needs, while enabling them to shop wherever, whenever, and however they want.

We strive to be a company, that is improving millions of pet lives as well as the lives of pet parents and the partners who work for us. In tandem with Petco Love, a life-changing independent nonprofit organization, we work with and support thousands of local animal welfare groups across the country and, through in-store adoption events, we have helped find homes for nearly 7 million animals.

Macroeconomic factors, including rising interest rates, inflationary pressures, supply chain constraints, and global economic and geopolitical developments have had varying impacts on our results of operations, such as decreases in sales of discretionary items like supplies, that are difficult to isolate and quantify. We cannot predict the duration or ultimate severity of these macroeconomic factors or the ultimate impact on our operations and liquidity. Please refer to the risk factors referred to in Part II, Item 1A, “*Risk Factors”* of this Form 10-Q.

### How We Assess the Performance of Our Business

In assessing our performance, we consider a variety of performance and financial measures, including the following:

### Comparable Sales

Comparable sales is an important measure throughout the retail industry and includes both retail and digital sales of products and services. A new location or digital site is included in comparable sales beginning on the first day of the fiscal month following 12 full fiscal months of operation and is subsequently compared to like time periods from the previous year. Relocated pet care centers become comparable pet care centers on the first day of operation if the original pet care center was open longer than 12 full fiscal months. If, during the period presented, a pet care center was closed, sales from that pet care center are included up to the first day of the month of closing. There may be variations in the way in which some of our competitors and other retailers calculate comparable sales. As a result, data in this filing regarding our comparable sales may not be comparable to similar data made available by other retailers.

Comparable sales allow us to evaluate how our overall ecosystem is performing by measuring the change in period-over-period net sales from locations and digital sites that have been open for the applicable period. We intend to improve comparable sales by continuing initiatives aimed to increase customer retention, frequency of visits, and basket size. General macroeconomic and retail business trends are also a key driver of changes in comparable sales.

### Non-GAAP Financial Measures

Management and our board of directors review, in addition to GAAP (as defined herein) measures, certain non-GAAP financial measures, including Adjusted EBITDA and Free Cash Flow, to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. Further explanations of these non-GAAP measures, along with reconciliations to their most comparable GAAP measures, are presented below under “Reconciliation of Non-GAAP Financial Measures to GAAP Measures.”

### Executive Summary

Comparing the thirteen weeks ended November 2, 2024 with the thirteen weeks ended October 28, 2023 (unless otherwise noted), our results included the following:

- an increase in net sales from $1.49 billion to $1.51 billion, representing a period-over-period increase of 1.2%;
- operating income of $4.0 million, compared to an operating loss of $1,232.1 million resulting primarily from goodwill impairment of $1,222.5 million in the prior year period;
- net loss attributable to Class A and B-1 common stockholders of $16.7 million, compared to net loss attributable to Class A and B-1 common stockholders of $1,241.1 million impacted by goodwill impairment in the prior year period; and
- an increase in Adjusted EBITDA from $72.2 million to $81.2 million.

### Results of Operations

The following tables summarize our results of operations and the percent of net sales of line items included in our consolidated statements of operations (dollars in thousands):

| Net sales: | Thirteen weeks ended November 2, 2024 | October 28, 2023 | Thirty-nine weeks ended November 2, 2024 | October 28, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Products | $1,263,194 | $1,257,803 | $3,806,674 | $3,852,997 |
| Services and other | 248,243 | 236,363 | 757,658 | 727,811 |
| Total net sales | 1,511,437 | 1,494,166 | 4,564,332 | 4,580,808 |
| Cost of sales: |  |  |  |  |
| Products | 782,240 | 787,994 | 2,362,065 | 2,366,472 |
| Services and other | 153,440 | 156,171 | 467,125 | 466,849 |
| Total cost of sales | 935,680 | 944,165 | 2,829,190 | 2,833,321 |
| Gross profit | 575,757 | 550,001 | 1,735,142 | 1,747,487 |
| Selling, general and administrative expenses | 571,780 | 559,611 | 1,745,479 | 1,705,443 |
| Goodwill impairment | — | 1,222,524 | — | 1,222,524 |
| Operating income (loss) | 3,977 | (1,232,134) | (10,337) | (1,180,480) |
| Interest income | (1,346) | (1,139) | (2,436) | (3,079) |
| Interest expense | 35,797 | 36,557 | 109,420 | 111,251 |
| Loss on partial extinguishment of debt | — | 174 | — | 920 |
| Other non-operating income | (8,465) | (113) | (5,800) | (4,727) |
| Loss before income taxes and income from equity method investees | (22,009) | (1,267,613) | (111,521) | (1,284,845) |
| Income tax benefit | (857) | (22,902) | (9,985) | (17,178) |
| Income from equity method investees | (4,479) | (3,574) | (13,557) | (10,032) |
| Net loss attributable to Class A and B-1 common stockholders | $(16,673) | $(1,241,137) | $(87,979) | $(1,257,635) |

18

| Net sales: | Thirteen weeks ended November 2, 2024 | October 28, 2023 | Thirty-nine weeks ended November 2, 2024 | October 28, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Products | 83.6% | 84.2% | 83.4% | 84.1% |
| Services and other | 16.4 | 15.8 | 16.6 | 15.9 |
| Total net sales | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of sales: |  |  |  |  |
| Products | 51.8 | 52.7 | 51.8 | 51.7 |
| Services and other | 10.1 | 10.5 | 10.2 | 10.2 |
| Total cost of sales | 61.9 | 63.2 | 62.0 | 61.9 |
| Gross profit | 38.1 | 36.8 | 38.0 | 38.1 |
| Selling, general and administrative expenses | 37.8 | 37.5 | 38.2 | 37.2 |
| Goodwill impairment | — | 81.8 | — | 26.7 |
| Operating income (loss) | 0.3 | (82.5) | (0.2) | (25.8) |
| Interest income | (0.1) | (0.1) | (0.1) | (0.1) |
| Interest expense | 2.5 | 2.4 | 2.4 | 2.5 |
| Loss on partial extinguishment of debt | — | 0.0 | — | 0.0 |
| Other non-operating income | (0.6) | (0.0) | (0.1) | (0.2) |
| Loss before income taxes and income from equity method investees | (1.5) | (84.8) | (2.4) | (28.0) |
| Income tax benefit | (0.1) | (1.5) | (0.2) | (0.4) |
| Income from equity method investees | (0.3) | (0.2) | (0.3) | (0.1) |
| Net loss attributable to Class A and B-1 common stockholders | (1.1)% | (83.1)% | (1.9)% | (27.5)% |

| Operational Data: | Thirteen weeks ended November 2, 2024 | October 28, 2023 | Thirty-nine weeks ended November 2, 2024 | October 28, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Comparable sales change | 1.8% | 0.0% | 0.3% | 2.8% |
| Total pet care centers at end of period | 1,413 | 1,429 | 1,413 | 1,429 |
| Adjusted EBITDA (in thousands) | $81,236 | $72,159 | $240,403 | $295,763 |

### Thirteen and Thirty-nine Weeks Ended November 2, 2024 Compared with Thirteen and Thirty-nine Weeks Ended October 28, 2023

### Net Sales and Comparable Sales

*(dollars in thousands)*

|  | Thirteen weeks ended November 2, 2024 | October 28, 2023 | $ Change | % Change | Thirty-nine weeks ended November 2, 2024 | October 28, 2023 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Consumables | $753,230 | $733,277 | $19,953 | 2.7% | $2,261,970 | $2,230,405 | $31,565 | 1.4% |
| Supplies and companion animals | 509,964 | 524,526 | (14,562) | (2.8%) | 1,544,704 | 1,622,592 | (77,888) | (4.8%) |
| Services and other | 248,243 | 236,363 | 11,880 | 5.0% | 757,658 | 727,811 | 29,847 | 4.1% |
| Net sales | $1,511,437 | $1,494,166 | $17,271 | 1.2% | $4,564,332 | $4,580,808 | $(16,476) | (0.4%) |

Net sales increased $17.3 million, or 1.2%, to $1.51 billion in the thirteen weeks ended November 2, 2024 compared to net sales of $1.49 billion in the thirteen weeks ended October 28, 2023. Net sales decreased $16.5 million, or 0.4%, to $4.56 billion in the thirty-nine weeks ended November 2, 2024 compared to net sales of $4.58 billion in the thirty-nine weeks ended October 28, 2023. We continue to experience momentum in consumables and services, although we have also experienced a decrease in supplies and companion animals sales driven by softening in discretionary spend associated with the current macroeconomic environment.

The comparison of consumables sales between the periods reflects the impact of prior year inflation, coupled with pricing actions taken in the third quarter of fiscal 2023. The decrease in supplies and companion animals sales is primarily due to a decrease in spending on certain non-essential items. The increase in services and other sales was primarily driven by a 8.6% and 9.7% increase in service-related sales during the thirteen and thirty-nine week periods ended November 2, 2024, respectively, reflecting maturity of our veterinary hospital footprint and growth in our veterinary and grooming businesses.

We are unable to quantify certain factors impacting sales described above due to the fact that such factors are based on input measures or qualitative information that do not lend themselves to quantification.

### Gross Profit

Gross profit increased $25.8 million, or 4.7%, to $575.8 million in the thirteen weeks ended November 2, 2024 compared to gross profit of $550.0 million for the thirteen weeks ended October 28, 2023. As a percentage of sales, our gross profit rate was 38.1% for the thirteen weeks ended November 2, 2024 compared with 36.8% for the thirteen weeks ended October 28, 2023, reflecting improvement in product mix and continued progress on product cost management. Gross profit decreased $12.3 million, or 0.7%, to $1,735.1 million in the thirty-nine weeks ended November 2, 2024 compared to gross profit of $1,747.5 million for the thirty-nine weeks ended October 28, 2023. As a percentage of sales, our gross profit rate was 38.0% for the thirty-nine weeks ended November 2, 2024 compared with 38.1% for the thirty-nine weeks ended October 28, 2023. The decrease in gross profit rate between the thirty-nine week periods was primarily due to the mix impact of higher consumables and services sales and softer supplies and companion animal sales during the thirty-nine weeks ended November 2, 2024. We are unable to quantify the factors impacting gross profit rate described above due to the fact that such factors are based on input measures or qualitative information that do not lend themselves to quantification.

### Selling, General and Administrative (“SG&A”) Expenses

SG&A expenses increased $12.2 million, or 2.2%, to $571.8 million for the thirteen weeks ended November 2, 2024 compared to $559.6 million for the thirteen weeks ended October 28, 2023. As a percentage of net sales, SG&A expenses were 37.8% for the thirteen weeks ended November 2, 2024 compared with 37.5% for the thirteen weeks ended October 28, 2023. The increase in SG&A expenses period-over-period included higher pet care center payroll and fringe benefits and bonuses, which was partially offset by a decrease in stock compensation and advertising expenses.

SG&A expenses increased $40.0 million, or 2.3%, to $1,745.5 million for the thirty-nine weeks ended November 2, 2024 compared to $1,705.4 million for the thirty-nine weeks ended October 28, 2023. As a percentage of net sales, SG&A expenses were 38.2% for the thirty-nine weeks ended November 2, 2024 compared with 37.2% for the thirty-nine weeks ended October 28, 2023. The increase in SG&A expenses included higher pet care center payroll and fringe benefits, bonuses, and store occupancy costs. This increase was partially offset by a decrease in stock compensation and advertising expenses.

### Goodwill Impairment

In the thirteen weeks ended October 28, 2023, the Company recorded a pre-tax goodwill impairment charge of $1.22 billion as a result of performing an interim impairment test in the third quarter of fiscal 2023 due to the identification of certain triggering events. For more information on this charge, refer to Note 3, *"Goodwill,"* to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

### Interest Expense

Interest expense decreased $0.8 million, or 2.1%, to $35.8 million in the thirteen weeks ended November 2, 2024 compared with $36.6 million in the thirteen weeks ended October 28, 2023. Interest expense decreased $1.9 million, or 1.6%, to $109.4 million in the thirty-nine weeks ended November 2, 2024 compared with $111.3 million in the thirty-nine weeks ended October 28, 2023. The decrease was primarily driven by pre-tax gains recognized in interest expense related to the Company's cash flow hedges during the thirteen and thirty-nine week periods ended November 2, 2024. For more information on derivative instruments, refer to Note 5, “*Derivative Instruments,”* to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

### Loss on Partial Extinguishment of Debt

There was no loss on debt extinguishment and modification for the thirteen and thirty-nine weeks ended November 2, 2024. Loss on partial extinguishment of debt was $0.2 million and $0.9 million for the thirteen and thirty-nine weeks ended October 28, 2023, respectively. This loss was recognized in conjunction with the $35.0 million, $25.0 million and $15.0 million repayments on the First Lien Term Loan in March 2023, May 2023 and August 2023, respectively. For more information regarding these activities, refer to Note 4, “*Senior Secured Credit Facilities,”* to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

### Other Non-Operating Income

Other non-operating income was $8.5 million and $5.8 million for the thirteen and thirty-nine weeks ended November 2, 2024, respectively, and were related to remeasurements of an equity investment without a readily determinable fair value. Other non-operating income was $0.1 million and 4.7 million for the thirteen and thirty-nine weeks ended October 28, 2023. For more information regarding this activity, refer to Note 6, “*Fair Value Measurements,”* to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

### Income Tax Benefit

Our effective tax rates were 4.9% and 10.2%, resulting in income tax benefit of $0.9 million and $10.0 million for the thirteen and thirty-nine weeks ended November 2, 2024, respectively, compared to effective tax rates of 1.8% and 1.3%, resulting in income tax benefit of $22.9 million and $17.2 million for the thirteen and thirty-nine weeks ended October 28, 2023, respectively. The change in effective tax rates for the thirteen and thirty-nine weeks ended November 2, 2024 was primarily driven by non-deductible goodwill impaired during the third quarter ending October 28, 2023, in addition to a shortfall in tax deductions resulting from the exercise and vesting of equity-based compensation awards for the periods.

### Reconciliation of Non-GAAP Financial Measures to GAAP Measures

The following information provides definitions and reconciliations of certain non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Such non-GAAP financial measures are not calculated in accordance with GAAP and should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the most comparable GAAP measures. The non-GAAP financial measures presented may differ from similarly-titled measures used by other companies.

### Adjusted EBITDA

We present Adjusted EBITDA, a non-GAAP financial measure, because we believe it enhances an investor’s understanding of our financial and operational performance by excluding certain material non-cash items, unusual or non-recurring items that we do not expect to continue in the future, and certain other adjustments we believe are or are not reflective of our ongoing operations and performance. Adjusted EBITDA enables operating performance to be reviewed across reporting periods on a consistent basis. We use Adjusted EBITDA as one of the principal measures to evaluate and monitor our operating financial performance and to compare our performance to others in our industry. We also use Adjusted EBITDA in connection with establishing discretionary annual incentive compensation targets, to make budgeting decisions, to make strategic decisions regarding the allocation of capital, and to report our quarterly results as defined in our debt agreements, although under such agreements the measure is calculated differently and is used for different purposes.

Adjusted EBITDA is not a substitute for net loss, the most comparable GAAP measure, and is subject to a number of limitations as a financial measure, so it should be used in conjunction with GAAP financial measures and not in isolation. There can be no assurances that we will not modify the presentation of Adjusted EBITDA in the future. In addition, other companies in our industry may define Adjusted EBITDA differently, limiting its usefulness as a comparative measure. Refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Reconciliation of Non-GAAP Financial Measures to GAAP Measures” included in the 2023 Form 10-K for more information regarding how we define Adjusted EBITDA.

The table below reflects the calculation of Adjusted EBITDA and Adjusted EBITDA Margin for the periods presented:

*(dollars in thousands)*

|  | Thirteen weeks ended November 2, 2024 | October 28, 2023 | Thirty-nine weeks ended November 2, 2024 | October 28, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Net loss attributable to Class A and B-1 common stockholders | $(16,673) | $(1,241,137) | $(87,979) | $(1,257,635) |
| Interest expense, net | 34,451 | 35,418 | 106,984 | 108,172 |
| Income tax benefit | (857) | (22,902) | (9,985) | (17,178) |
| Depreciation and amortization | 50,109 | 50,674 | 149,414 | 148,593 |
| Income from equity method investees | (4,479) | (3,574) | (13,557) | (10,032) |
| Loss on partial extinguishment of debt | — | 174 | — | 920 |
| Goodwill impairment | — | 1,222,524 | — | 1,222,524 |
| Asset impairments and write offs | 1,380 | 1,167 | 8,449 | 2,202 |
| Equity-based compensation | 11,357 | 18,183 | 40,705 | 64,431 |
| Other non-operating income | (8,465) | (113) | (5,800) | (4,727) |
| Mexico joint venture EBITDA (1) | 9,984 | 9,189 | 30,382 | 26,467 |
| Acquisition and divestiture-related costs (2) | — | — | 3,719 | — |
| Other costs (3) | 4,429 | 2,556 | 18,071 | 12,026 |
| Adjusted EBITDA | $81,236 | $72,159 | $240,403 | $295,763 |
| Net sales | $1,511,437 | $1,494,166 | $4,564,332 | $4,580,808 |
| Net margin (4) | (1.1)% | (83.1)% | (1.9)% | (27.5)% |
| Adjusted EBITDA Margin | 5.4% | 4.8% | 5.3% | 6.5% |

(1) Mexico joint venture EBITDA represents 50% of the entity’s operating results for the periods presented, as adjusted to reflect the results on a basis comparable to our Adjusted EBITDA. In the financial statements, this joint venture is accounted for as an equity method investment and reported net of depreciation and income taxes. Because such a presentation would not reflect the adjustments made in our calculation of Adjusted EBITDA, we include our 50% interest in our Mexico joint venture on an Adjusted EBITDA basis to ensure consistency. The table below presents a reconciliation of Mexico joint venture net income to Mexico joint venture EBITDA:

*(dollars in thousands)*

|  | Thirteen weeks ended November 2, 2024 | October 28, 2023 | Thirty-nine weeks ended November 2, 2024 | October 28, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Net income | $8,958 | $7,149 | $27,335 | $20,064 |
| Depreciation | 6,880 | 6,920 | 20,824 | 19,071 |
| Income tax expense | 3,637 | 2,470 | 10,996 | 8,908 |
| Foreign currency (gain) loss | (106) | 441 | (7) | 963 |
| Interest expense, net | 599 | 1,397 | 1,615 | 3,927 |
| EBITDA | $19,968 | $18,377 | $60,763 | $52,933 |
| 50% of EBITDA | $9,984 | $9,189 | $30,382 | $26,467 |

(2) Acquisition and divestiture-related costs include direct costs resulting from acquiring, integrating, or divesting businesses. These include third-party professional and legal fees, losses on sales of divestitures, and other integration-related costs that would not have otherwise been incurred as part of the Company's operations.

(3) Other costs include, as incurred: restructuring costs and restructuring-related severance costs; legal reserves associated with significant, non-ordinary course legal or regulatory matters; and costs related to certain significant strategic transactions.

(4) We define net margin as net loss attributable to Class A and B-1 common stockholders divided by net sales and Adjusted EBITDA margin as Adjusted EBITDA divided by net sales.

### Free Cash Flow

Free Cash Flow is a non-GAAP financial measure that is calculated as net cash provided by operating activities less cash paid for fixed assets. Management believes that Free Cash Flow, which measures our ability to generate additional cash from our business operations, is an important financial measure for use in evaluating the Company’s financial performance.

The table below reflects the calculation of Free Cash Flow for the periods presented:

*(dollars in thousands)*

|  | Thirty-nine weeks ended November 2, 2024 | October 28, 2023 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $81,680 | $168,696 |
| Cash paid for fixed assets | (91,041) | (176,532) |
| Free Cash Flow | $(9,361) | $(7,836) |

### Liquidity and Capital Resources

### Overview

Our primary sources of liquidity are funds generated by operating activities and available capacity for borrowings on our $581 million secured asset-based revolving credit facility (as amended, the “ABL Revolving Credit Facility”). Our ability to fund our operations, to make planned capital investments, to make scheduled debt payments and to repay or refinance indebtedness depends on our future operating performance and cash flows, which are subject to prevailing economic conditions and financial, business, and other factors, some of which are beyond our control. Our liquidity as of November 2, 2024 was $644.3 million, inclusive of cash and cash equivalents of $116.7 million and $527.6 million of availability on the ABL Revolving Credit Facility.

We are a party to contractual obligations involving commitments to make payments to third parties. These obligations impact our short-term and long-term liquidity and capital resource needs. We believe that our current resources, together with anticipated cash flows from operations and borrowing capacity under the ABL Revolving Credit Facility will be sufficient to finance our operations, meet our current cash requirements, and fund anticipated capital investments for at least the next 12 months. We may, however, seek additional financing to fund future growth or refinance our existing indebtedness through the debt capital markets, but we cannot be assured that such financing will be available on favorable terms, or at all.

### Cash Flows

The following table summarizes our consolidated cash flows:

*(dollars in thousands)*

| Total cash provided by (used in): | Thirty-nine weeks ended November 2, 2024 | October 28, 2023 |
| --- | ---: | ---: |
| Operating activities | $81,680 | $168,696 |
| Investing activities | (89,506) | (156,149) |
| Financing activities | (7,802) | (84,040) |
| Net decrease in cash, cash equivalents and restricted cash | $(15,628) | $(71,493) |

### Operating Activities

Our primary source of operating cash is sales of products and services to customers, which are substantially all on a cash basis, and therefore provide us with a significant source of liquidity. Our primary uses of cash in operating activities include: purchases of inventory; freight and warehousing costs; employee-related expenditures; occupancy-related costs for our pet care centers, distribution centers and corporate support centers; credit card fees; interest under our debt agreements; and marketing expenses. Net cash provided by operating activities is impacted by our net loss adjusted for certain non-cash items, including: depreciation, amortization, impairments and write-offs; amortization of debt discounts and issuance costs; deferred income taxes; equity-based compensation; impairments of goodwill and intangible assets; other non-operating income; and the effect of changes in operating assets and liabilities.

Net cash provided by operating activities was $81.7 million in the thirty-nine weeks ended November 2, 2024 compared with net cash provided by operating activities of $168.7 million in the thirty-nine weeks ended October 28, 2023. The decrease in operating cash flow was driven by an increase in cash paid for inventory, which was partially offset by decreases in cash paid for advertising, freight, and operating leases as well as other timing differences in accounts payable.

### Investing Activities

Net cash used in investing activities was $89.5 million and $156.1 million for the thirty-nine weeks ended November 2, 2024 and October 28, 2023, respectively. This decrease was primarily driven by reductions in capital spend, reflecting fewer anticipated hospital build-outs and a balanced approach between focused investments and cash flow.

### Financing Activities

Net cash used in financing activities was $7.8 million for the thirty-nine weeks ended November 2, 2024, compared with $84.0 million used in financing activities in the thirty-nine weeks ended October 28, 2023.

Financing cash flows in the thirty-nine weeks ended November 2, 2024 primarily consisted of borrowings and repayments on the ABL Revolving Credit Facility.

Financing cash flows in the thirty-nine weeks ended October 28, 2023 primarily consisted of $75.0 million in principal repayments on the term loan.

### Sources of Liquidity

### Senior Secured Credit Facilities

On March 4, 2021, the Company completed a refinancing transaction by entering into a $1,700 million secured term loan facility maturing on March 4, 2028 (the “First Lien Term Loan”) and the ABL Revolving Credit Facility, maturing on March 4, 2026 with availability of up to $500.0 million, subject to a borrowing base.

In March 2024, the Company amended the ABL Revolving Credit Facility, which now consists of two tranches, to increase its total availability from $500.0 million to $581.0 million and extend the maturity on a portion of this availability. The first tranche has availability of up to $35.0 million, subject to a borrowing base, maturing on March 4, 2026. The second tranche has availability of up to $546.0 million, subject to a borrowing base, maturing on March 29, 2029. Interest on the ABL Revolving Credit Facility is now based on, at the Company's option, either the base rate subject to a 1% floor, or Term SOFR subject to a floor of 0%, plus an applicable margin. All other key terms of the ABL Revolving Credit Facility remained unchanged.

Interest on the First Lien Term Loan is based on, at the Company’s option, either a base rate or Adjusted Term SOFR, subject to a 0.75% floor, payable upon maturity of the SOFR contract, in either case plus the applicable rate. The base rate is the greater of the bank prime rate, federal funds effective rate plus 0.5% or Adjusted Term SOFR plus 1.0%. The applicable rate is 2.25% per annum for a base rate loan or 3.25% per annum for an Adjusted Term SOFR loan. Principal and interest payments commenced on June 30, 2021. Principal payments are typically $4.25 million quarterly. During the thirty-nine weeks ended October 28, 2023, the Company repaid $75.0 million in principal of the First Lien Term Loan using existing cash on hand. The repayments were applied to remaining principal payments in order of scheduled payment date.

For more information regarding this indebtedness, refer to Note 4, “*Senior Secured Credit Facilities,”* to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

### Derivative Instruments

The Company entered into interest rate cap, collar and swap agreements to limit the maximum interest on a portion of the Company’s variable-rate debt and decrease its exposure to interest rate variability relating to three-month Term SOFR. For more information regarding derivative instruments, refer to Note 5, “*Derivative Instruments,”* to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

### Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires us to make assumptions and estimates about future results and apply judgments that affect the reported amounts of assets, liabilities, net sales, expenses and related disclosures. We base our estimates and judgments on historical experience, current trends and other factors that we believe to be relevant at the time our consolidated financial statements are prepared. On an ongoing basis, we review the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

### Goodwill and Trade Name Intangible Assets

### Goodwill

We evaluate goodwill annually in our fourth quarter or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We have identified one reporting unit and selected our fourth fiscal quarter to perform our annual goodwill impairment testing. Goodwill impairment guidance provides entities the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The qualitative assessment requires significant judgments about economic conditions, including the entity’s operating environment, its industry and other market conditions, entity-specific events related to financial performance or loss of key personnel, and other events that could impact the reporting unit. If management concludes, based on assessment of relevant events, facts, and circumstances, that it is more likely than not that a reporting unit’s fair value is greater than its carrying value, no further impairment testing is required.

If management’s assessment of qualitative factors indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then a quantitative assessment is performed. We also have the option to bypass the qualitative assessment described above and proceed directly to the quantitative assessment, where we compare the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of our net assets assigned to that unit, goodwill is not considered impaired, and we are not required to perform further testing. If the carrying value of net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then we would record an impairment loss equal to the difference. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by reviewing transactional and financial data of publicly traded companies. The assumptions used in the impairment analysis are inherently subject to uncertainty and small changes in these assumptions could have a significant impact on the concluded value. The Company's market capitalization is also considered as part of the analysis, in order to further validate the reasonableness of the fair values concluded for the reporting unit. Factors that may trigger an interim impairment test may include, but are not limited to, current economic and market conditions or a significant decline in the Company's share price and market capitalization compared to net book value.

### Indefinite-lived trade name

We consider the Petco trade name to be an indefinite-lived intangible asset, as we currently anticipate that this trade name will contribute cash flows to us indefinitely. We perform our annual impairment test during the fourth quarter of each year or whenever events or changes in circumstances indicate the carrying value may not be recoverable. Management has the option to first perform a qualitative assessment of its trade name asset to determine whether it is necessary to perform a quantitative impairment test. We also have the option to bypass the qualitative assessment described above and proceed directly to quantitative assessment.

Factors that may trigger an interim impairment test may include, but are not limited to, a significant decline in the Company's share price and market capitalization compared to net book value, or changes in the pattern of utilization of the intangible asset. Significant assumptions used in the determination of fair value of the trade name generally include prospective financial information, growth rates, discount rates and comparable multiples from publicly traded companies in similar industries. An impairment charge is recorded for the amount by which the carrying amount of the trade name exceeds its fair value.

There have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates described in the 2023 Form 10-K.

### Recent Accounting Pronouncements

Refer to Note 1, “*Summary of Significant Accounting Policies,”* to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q for information regarding recently issued accounting pronouncements.

## Market risk

As filed, 2,640 characters.

We are subject to market risks arising from transactions in the normal course of our business. These risks are primarily associated with interest rate fluctuations, as well as changes in our credit standing, based on the capital and credit markets, which are not predictable. We do not currently hold any instruments for trading purposes.

### Interest Rate Risk

We are subject to interest rate risk in connection with the First Lien Term Loan and the ABL Revolving Credit Facility. As of November 2, 2024, we had $1,595.3 million outstanding under the First Lien Term Loan and no amounts outstanding under the ABL Revolving Credit Facility. The First Lien Term Loan and the ABL Revolving Credit Facility each bear interest at variable rates. An increase of 100 basis points in the variable rates on the First Lien Term Loan and the ABL Revolving Credit Facility as of November 2, 2024 would have increased annual cash interest in the aggregate by approximately $16.2 million. Additionally, we entered into cash flow hedges to limit the maximum interest rate on a portion of our variable-rate debt and limit our exposure to interest rate variability, refer to Note 5, “*Derivative Instruments,”* to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

We cannot predict market fluctuations in interest rates and their impact on our debt, nor can there be any assurance that long-term fixed-rate debt will be available at favorable rates, if at all. Consequently, future results may differ materially from estimated results due to adverse changes in interest rates or debt availability.

### Credit Risk

As of November 2, 2024, our cash and cash equivalents were maintained at major financial institutions in the United States, and our current deposits are likely in excess of insured limits. We believe these institutions have sufficient assets and liquidity to conduct their operations in the ordinary course of business with little or no credit risk to us.

### Foreign Currency Risk

Substantially all of our business is currently conducted in U.S. dollars, with a small amount denominated in foreign currencies. Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations. Our results of current and future operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. We do not enter into forward currency contracts to hedge our foreign currency exposure. A hypothetical 10% change in foreign currency exchange rates applicable to our business would not have a material effect on our operating results.

## Controls and procedures

As filed, 2,172 characters.

### Management’s Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required financial disclosure.

As of the end of the period covered by this Form 10-Q, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(e) and 15d-15(e). Based upon this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of November 2, 2024.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended November 2, 2024 which has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on the Effectiveness of Controls

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based on certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

## Risk factors

As filed, 865 characters.

Reference is made to Part I, Item 1A, “*Risk Factors”* included in the 2023 Form 10-K and Part II, Item 1A, “*Risk Factors”* included in our Quarterly Report on Form 10-Q for the quarter ended May 4, 2024 (the “Q1 Form 10-Q”) for information concerning risk factors. Except as set forth in the Q1 Form 10-Q, there have been no material changes with respect to the risk factors disclosed in the 2023 Form 10-K. You should carefully consider such factors, which could materially and adversely affect our business, financial condition and/or results of operations. The risks described in the Q1 Form 10-Q and the 2023 Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or results of operations.

Filed Dec 6, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-134077. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.